| Biomarker ID | 920 |
| PMID | 22589396 |
| Year | 2012 |
| Biomarker | Deoxycarnitine; Acetylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Laurylcarnitine; Palmitoylcarnitine; Stearoylcarnitine; Oleoylcarnitine; 3-hydroxybutyrate (BHBA); Acetoacetate; Dodecanedioate; Octadecanedioate; |
| Biomarker Basis | Expression Based |
| Biomolecule | Metabolites |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Differentially expressed [ Deoxycarnitine (0.89 fold); Acetylcarnitine (0.80 fold); Hexanoylcarnitine (0.80 fold_; Octanoylcarnitine (0.72 fold); Decanoylcarnitine (0.71 fold); Laurylcarnitine (0.65 fold); Palmitoylcarnitine (0.82 fold0; Stearoylcarnitine (0.77 fold); Oleoylcarnitine (0.88 fold); 3-hydroxybutyrate (BHBA) (0.36 fold); Acetoacetate (0.52 fold); Dodecanedioate (0.80 fold); Octadecanedioate (0.73 fold);] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Effect of Androgen deprivation therapy (ADT) baseline to 3 months |
| Type of Biomarker | Predictive |
| Cohort | 36 subjects at baseline and after 3 months of gonadotropin releasing hormone (GnRH) agonist therapy |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | <0.05 |
| Method Used | gas chromatography-mass spectrometry and liquid chromatography/tandem mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |